

Corrigendum to “Assessing cardiac safety in oncology drug development” [*Am Heart J* 214 (2019) 125-133]



Jonathan H. Seltzer MD, MBA, MA, Gary Gintant PhD, Laleh Amiri-Kordestani MD, Jack Singer MD, Luana Pesco Koplowitz MD, PhD, Javid J. Moslehi MD, Ana Barac MD, PhD, Anthony F. Yu MD

^a*ACI Clinical, Bala Cynwyd, PA* ^{ACI Clinical} ^{Bala Cynwyd} ^{PA}

The authors regret that her contributions were not properly acknowledged.

The authors wish to thank Dr Bonnie Ky for providing Figures 1 and 2. Additionally, some of the text from her presentation slides was referred to in the body of the manuscript.

The authors would like to apologize for any inconvenience caused.

From the ^a*ACI Clinical, Bala Cynwyd, PA*, ^b*Abbvie, North Chicago, IL*, ^c*FDA, Silver Spring, MD*, ^d*Washington State University, CTI Biopharma, Seattle, WA*, ^e*DUCK FLATS Pharma, Elbridge, NY*, ^f*Vanderbilt University Medical Center, Nashville, TN*, ^g*Georgetown University/Medstar Health, Washington, DC*, and ^h*Memorial Sloan Kettering, New York, NY*.

Reprint requests: Jonathan Seltzer, *ACI Clinical, Bala Cynwyd, PA*.

E-mail: jseltzer@aciclinical.com

0002-8703

© 2019 The Author(s). Published by Elsevier Inc. All rights reserved.

<https://doi.org/10.1016/j.ahj.2019.08.006>